U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H9Cl3N2OS
Molecular Weight 359.6595
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRICLABENDAZOLE

SMILES

CSc1[nH]c2cc(c(cc2n1)Oc3cccc(c3Cl)Cl)Cl

InChI

InChIKey=NQPDXQQQCQDHHW-UHFFFAOYSA-N
InChI=1S/C14H9Cl3N2OS/c1-21-14-18-9-5-8(16)12(6-10(9)19-14)20-11-4-2-3-7(15)13(11)17/h2-6H,1H3,(H,18,19)

HIDE SMILES / InChI

Molecular Formula C14H9Cl3N2OS
Molecular Weight 359.6595
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.drugs.com/international/triclabendazole.html | https://www.drugs.com/mmx/triclabendazole.html | https://www.ncbi.nlm.nih.gov/pubmed/15259481 | https://www.ncbi.nlm.nih.gov/pubmed/26312936

Triclabendazole, (brand name Avomec, Egaten, etc) is a member of the benzimidazole family of anthelmintics used to treat liver flukes, specifically fascioliasis and paragonimiasis. Triclabendazole used routinely since 1983 in veterinary practice for the treatment of fascioliasis. It was not used in humans until the 1989 epidemic of fascioliasis near the Caspian Sea when Iranian authorities approved the use of the veterinary formulation to treat the infection. Fasciolicidal not only against the adult worms present in the biliary ducts, but also against the immature larval stages of Fasciola migrating through the hepatic parenchyma. Triclabendazole is shown to penetrate into liver flukes by transtegumentary absorption followed by inhibition of the parasite's motility, probably related to the destruction of the microtubular structure, resulting in the death of the parasite; the immobilizing effect is paralleled by changes in the parasite's resting tegumental membrane potential, strongly inhibiting the release of proteolytic enzymes, a process that appears critical to the survival of the parasite. Side effects are generally few, but can include abdominal pain and headaches. Biliary colic may occur due to dying worms. While no harms have been found with use during pregnancy, triclabendazole has not been well studied in this population. Triclabendazole is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is not commercially available in the United States.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
15.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Egaten

Approved Use

Unknown
Curative
Egaten

Approved Use

Unknown
Curative
Egaten

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.34 μM
10 mg/kg 1 times / day multiple, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.16 μM
10 mg/kg 1 times / day multiple, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
1.16 μM
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.55 μM × h
10 mg/kg 1 times / day multiple, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.72 μM × h
10 mg/kg 1 times / day multiple, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
5.72 μM × h
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8 h
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3.3%
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 12-60 years
n = 47
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 12-60 years
Sex: M+F
Population Size: 47
Sources:
Other AEs: Abdominal pain, Headache...
Other AEs:
Abdominal pain (6.4%)
Headache (10.6%)
Dizziness (4.3%)
Jaundice (2.1%)
Sources:
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 4-68 years
n = 154
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 4-68 years
Sex: M+F
Population Size: 154
Sources:
Other AEs: Dizziness, Abdominal pain...
Other AEs:
Dizziness (5.4%)
Abdominal pain (1.3%)
Diarrhea (1.3%)
Fever (1.9%)
Sources:
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 5-54 years
n = 35
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 5-54 years
Sex: M+F
Population Size: 35
Sources:
Other AEs: Headache, Abdominal pain...
Other AEs:
Headache (5.7%)
Abdominal pain (5.7%)
Vomiting (2.9%)
Diarrhea (2.9%)
Sources:
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 82
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 82
Sources:
Other AEs: Abdominal pain, Biliary colic...
Other AEs:
Abdominal pain (grade 3, 1.2%)
Biliary colic (grade 1-2, 49%)
Jaundice (grade 1-2, 7.2%)
Epigastric pain (grade 1-2, 42.7%)
Nausea (grade 1-2, 8.5%)
Fever (grade 1-2, 8.5%)
Pruritus (grade 1-2, 6.1%)
Urticaria (grade 1-2, 2.4%)
Sources:
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
Other AEs: Abdominal pain, Hyperhidrosis...
Other AEs:
Abdominal pain (93%)
Hyperhidrosis (25%)
Nausea (18%)
Urticaria (11%)
Vomiting (7%)
Headache (14%)
Pruritus (4%)
Musculoskeletal chest pain (4%)
Decreased appetite (18%)
Diarrhea (7%)
Sources:
15 mg/kg single, oral (mean)
Recommended
Dose: 15 mg/kg
Route: oral
Route: single
Dose: 15 mg/kg
Sources:
unhealthy, adult | children
n = 214
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 214
Sources:
Other AEs: Bilirubin increased, AST increased...
Other AEs:
Bilirubin increased (6.8%)
AST increased (4.5%)
Alkaline phosphatase increased (4.2%)
ALT increased (3%)
Sources:
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Other AEs: Abdominal pain, Hyperhidrosis...
Other AEs:
Abdominal pain (56%)
Hyperhidrosis (23%)
Vertigo (9%)
Nausea (8%)
Urticaria (7%)
Vomiting (6%)
Headache (6%)
Dyspnea (5%)
Pruritus (4%)
Asthenia (4%)
Musculoskeletal chest pain (4%)
Cough (4%)
Decreased appetite (3%)
Chest pain (3%)
Pyrexia (2%)
Jaundice (2%)
Chest discomfort (2%)
Constipation (< 2%)
Biliary colic (< 2%)
Arthralgia (< 2%)
Back pain (< 2%)
Spinal pain (< 2%)
Chromaturia (< 2%)
Sources:
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age 16.3 years
n = 4
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age 16.3 years
Sex: M+F
Population Size: 4
Sources:
Other AEs: Abdominal pain, Fatigue...
Other AEs:
Abdominal pain (grade 1, 100%)
Fatigue (grade 1, 50%)
Headache (grade 1-2, 75%)
Diarrhea (grade 1, 25%)
Nausea (grade 1, 75%)
Vomiting (grade 1, 25%)
Fever (grade 1-2, 25%)
Dizziness (grade 1, 50%)
Sources:
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age14.4 years
n = 16
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age14.4 years
Sex: M+F
Population Size: 16
Sources:
Other AEs: Abdominal pain, Fatigue...
Other AEs:
Abdominal pain (grade 1-2)
Fatigue (grade 1)
Headache (grade 1-2)
Diarrhea (grade 1-2)
Vomiting (grade 1)
Fever (grade 1-2)
Dizziness (grade 1)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache 10.6%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 12-60 years
n = 47
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 12-60 years
Sex: M+F
Population Size: 47
Sources:
Jaundice 2.1%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 12-60 years
n = 47
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 12-60 years
Sex: M+F
Population Size: 47
Sources:
Dizziness 4.3%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 12-60 years
n = 47
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 12-60 years
Sex: M+F
Population Size: 47
Sources:
Abdominal pain 6.4%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 12-60 years
n = 47
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 12-60 years
Sex: M+F
Population Size: 47
Sources:
Abdominal pain 1.3%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 4-68 years
n = 154
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 4-68 years
Sex: M+F
Population Size: 154
Sources:
Diarrhea 1.3%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 4-68 years
n = 154
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 4-68 years
Sex: M+F
Population Size: 154
Sources:
Fever 1.9%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 4-68 years
n = 154
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 4-68 years
Sex: M+F
Population Size: 154
Sources:
Dizziness 5.4%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 4-68 years
n = 154
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 4-68 years
Sex: M+F
Population Size: 154
Sources:
Diarrhea 2.9%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 5-54 years
n = 35
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 5-54 years
Sex: M+F
Population Size: 35
Sources:
Vomiting 2.9%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 5-54 years
n = 35
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 5-54 years
Sex: M+F
Population Size: 35
Sources:
Abdominal pain 5.7%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 5-54 years
n = 35
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 5-54 years
Sex: M+F
Population Size: 35
Sources:
Headache 5.7%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
unhealthy, 5-54 years
n = 35
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 5-54 years
Sex: M+F
Population Size: 35
Sources:
Urticaria grade 1-2, 2.4%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 82
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 82
Sources:
Epigastric pain grade 1-2, 42.7%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 82
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 82
Sources:
Biliary colic grade 1-2, 49%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 82
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 82
Sources:
Pruritus grade 1-2, 6.1%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 82
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 82
Sources:
Jaundice grade 1-2, 7.2%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 82
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 82
Sources:
Fever grade 1-2, 8.5%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 82
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 82
Sources:
Nausea grade 1-2, 8.5%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 82
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 82
Sources:
Abdominal pain grade 3, 1.2%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 82
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 82
Sources:
Urticaria 11%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
Headache 14%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
Decreased appetite 18%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
Nausea 18%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
Hyperhidrosis 25%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
Musculoskeletal chest pain 4%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
Pruritus 4%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
Diarrhea 7%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
Vomiting 7%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
Abdominal pain 93%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
ALT increased 3%
15 mg/kg single, oral (mean)
Recommended
Dose: 15 mg/kg
Route: oral
Route: single
Dose: 15 mg/kg
Sources:
unhealthy, adult | children
n = 214
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 214
Sources:
Alkaline phosphatase increased 4.2%
15 mg/kg single, oral (mean)
Recommended
Dose: 15 mg/kg
Route: oral
Route: single
Dose: 15 mg/kg
Sources:
unhealthy, adult | children
n = 214
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 214
Sources:
AST increased 4.5%
15 mg/kg single, oral (mean)
Recommended
Dose: 15 mg/kg
Route: oral
Route: single
Dose: 15 mg/kg
Sources:
unhealthy, adult | children
n = 214
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 214
Sources:
Bilirubin increased 6.8%
15 mg/kg single, oral (mean)
Recommended
Dose: 15 mg/kg
Route: oral
Route: single
Dose: 15 mg/kg
Sources:
unhealthy, adult | children
n = 214
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 214
Sources:
Chest discomfort 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Jaundice 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Pyrexia 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Hyperhidrosis 23%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Chest pain 3%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Decreased appetite 3%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Asthenia 4%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Cough 4%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Musculoskeletal chest pain 4%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Pruritus 4%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Dyspnea 5%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Abdominal pain 56%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Headache 6%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Vomiting 6%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Urticaria 7%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Nausea 8%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Vertigo 9%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Arthralgia < 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Back pain < 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Biliary colic < 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Chromaturia < 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Constipation < 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Spinal pain < 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
Abdominal pain grade 1, 100%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age 16.3 years
n = 4
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age 16.3 years
Sex: M+F
Population Size: 4
Sources:
Diarrhea grade 1, 25%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age 16.3 years
n = 4
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age 16.3 years
Sex: M+F
Population Size: 4
Sources:
Vomiting grade 1, 25%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age 16.3 years
n = 4
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age 16.3 years
Sex: M+F
Population Size: 4
Sources:
Dizziness grade 1, 50%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age 16.3 years
n = 4
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age 16.3 years
Sex: M+F
Population Size: 4
Sources:
Fatigue grade 1, 50%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age 16.3 years
n = 4
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age 16.3 years
Sex: M+F
Population Size: 4
Sources:
Nausea grade 1, 75%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age 16.3 years
n = 4
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age 16.3 years
Sex: M+F
Population Size: 4
Sources:
Fever grade 1-2, 25%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age 16.3 years
n = 4
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age 16.3 years
Sex: M+F
Population Size: 4
Sources:
Headache grade 1-2, 75%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age 16.3 years
n = 4
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age 16.3 years
Sex: M+F
Population Size: 4
Sources:
Dizziness grade 1
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age14.4 years
n = 16
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age14.4 years
Sex: M+F
Population Size: 16
Sources:
Fatigue grade 1
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age14.4 years
n = 16
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age14.4 years
Sex: M+F
Population Size: 16
Sources:
Vomiting grade 1
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age14.4 years
n = 16
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age14.4 years
Sex: M+F
Population Size: 16
Sources:
Abdominal pain grade 1-2
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age14.4 years
n = 16
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age14.4 years
Sex: M+F
Population Size: 16
Sources:
Diarrhea grade 1-2
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age14.4 years
n = 16
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age14.4 years
Sex: M+F
Population Size: 16
Sources:
Fever grade 1-2
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age14.4 years
n = 16
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age14.4 years
Sex: M+F
Population Size: 16
Sources:
Headache grade 1-2
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
unhealthy, mean age14.4 years
n = 16
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age14.4 years
Sex: M+F
Population Size: 16
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
yes [Ki 0.009 uM]
yes [Ki 0.016 uM]
yes [Ki 0.018 uM]
yes [Ki 0.05 uM]
yes [Ki 0.053 uM]
yes [Ki 0.061 uM]
yes [Ki 0.149 uM]
yes [Ki 0.166 uM]
yes [Ki 0.22 uM]
yes [Ki 0.37 uM]
yes [Ki 0.57 uM]
yes [Ki 0.75 uM]
yes [Ki 1.03 uM]
yes [Ki 1.27 uM]
yes [Ki 1.81 uM]
yes [Ki 12.5 uM]
yes [Ki 13 uM]
yes [Ki 2.31 uM]
yes [Ki 2.77 uM]
yes [Ki 4.32 uM]
yes
yes
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Experimental infection of rabbits with Fasciola gigantica and treatment with triclabendazole (TCBZ) or BT6: parasitological, haematological and immunological findings.
2001
[A clinical trial of triclabendazole in the treatment of human paragonimiasis skrjabini].
2001
Efficacy of combined chemotherapy against gastrointestinal nematodes and Fasciola hepatica in cattle.
2001 Aug 20
An experimental study on triclabendazole resistance of Fasciola hepatica in sheep.
2001 Feb
A comparative study on the effect of praziquantel and triclabendazole on Vampirolepis nana in vitro.
2002 Apr
[Chilhood hepatic fascioliasis treated with triclabendazol].
2002 Aug
Pathological and immunohistochemical study of the liver and hepatic lymph nodes of sheep chronically reinfected with Fasciola hepatica, with or without triclabendazole treatment.
2002 Jul
A praziquantel-ineffective fascioliasis case successfully treated with triclabendazole.
2002 Jun
Antioxidant capacity in Fasciola hepatica patients before and after treatment with triclabendazole alone or in combination with ascorbic acid (vitamin C) and tocofersolan (vitamin E).
2003
Pediatric fascioliasis: report of three cases.
2003 Jan-Mar
Comparison of two single-day regimens of triclabendazole for the treatment of human pulmonary paragonimiasis.
2003 Jul-Aug
The effect of the microtubule inhibitor tubulozole-C on the tegument of triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica.
2003 Sep
Chemotherapy for major food-borne trematodes: a review.
2004 Aug
Liver, spleen, pancreas and kidney involvement by human fascioliasis: imaging findings.
2004 Aug 4
Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro.
2004 Dec
Comparative assessment of the access of albendazole, fenbendazole and triclabendazole to Fasciola hepatica: effect of bile in the incubation medium.
2004 Jan
Human fascioliasis.
2004 May
Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis.
2004 Nov
[Human infection with Dicrocoelium dendriticum].
2004 Nov 19
Triclabendazole biotransformation and comparative diffusion of the parent drug and its oxidized metabolites into Fasciola hepatica.
2004 Nov-Dec
Measurement of triclabendazole and its metabolites in liver flukes: method development and full validation.
2004 Sep 3
Monitoring and treatment of Fascioloides magna in semi-farm red deer husbandry in Croatia.
2005 Aug
Phenotype of hepatic infiltrates and hepatic lymph nodes of lambs primarily and challenge infected with Fasciola hepatica, with and without triclabendazole treatment.
2005 Jan-Feb
[Four cases of hepatic fascioliasis mimicking cholangiocarcinoma].
2005 Jun
[Obstructive jaundice, Fasciola hepatica: a new case report].
2005 May-Aug
Infection with Fasciola hepatica.
2005 Nov
Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes.
2005 Oct
Triclabendazole: new skills to unravel an old(ish) enigma.
2005 Sep
[Therapeutic alternatives in case of failure of first-line treatment of intestinal helminthiasis in adults].
2006 Aug
Triclabendazole and its two main metabolites lack activity against Schistosoma mansoni in the mouse model.
2006 Aug
Adult triclabendazole-resistant Fasciola hepatica: surface and subsurface tegumental responses to in vitro treatment with the sulphoxide metabolite of the experimental fasciolicide compound alpha.
2006 Aug
Stage-specific differences in fecundity over the life-cycle of two characterized isolates of the liver fluke, Fasciola hepatica.
2006 Aug
Response from Savioli and colleagues from the Department of Neglected Tropical Diseases, World Health Organization.
2006 Jun
Assessment of the main metabolism pathways for the flukicidal compound triclabendazole in sheep.
2006 Jun
Fasciola hepatica infection: clinical and computerized tomographic findings of ten patients.
2006 Mar
Systemic vasculitis associated with Fasciola hepatica infection.
2006 Mar-Apr
[Hepatobiliary fasciolasis without eosinophilia].
2006 Oct
Fasciola hepatica: morphological effects of a combination of triclabendazole and clorsulon against mature fluke.
2006 Oct
Resistance of Fasciola hepatica to triclabendazole and albendazole in sheep in Spain.
2006 Sep 23
Surgery in Fasciola hepatica pancreatitis: report of a case and review of literature.
2007 Apr
Activity of artemether and OZ78 against triclabendazole-resistant Fasciola hepatica.
2007 Dec
Immature triclabendazole-resistant Fasciola hepatica: tegumental responses to in vitro treatment with the sulphoxide metabolite of the experimental fasciolicide compound alpha.
2007 Jan
An in vitro effect of propolis on adult worms of Fasciola gigantica.
2007 Mar 31
[Fascioliasis: a 23-year retrospective study].
2007 Nov
Fasciola hepatica: the infectivity of cattle-origin miracidia had increased over the past years in central France.
2007 Sep
A field trial of production and financial consequences of helminthosis control in sheep production in Ethiopia.
2008 Apr 17
Natural history, clinicoradiologic correlates, and response to triclabendazole in acute massive fascioliasis.
2008 Feb
Use of triclabendazole for treatment of patients co-infected by Fasciola spp. and S. mansoni in Behera Governorate, Egypt.
2008 Mar
Patents

Sample Use Guides

10 mg per kg of body weight as a single dose
Route of Administration: Oral
Triclabendazole was tested in vitro against recently excysted metacercariae. Triclabendazole was evaluated at concentrations of 10 and 50 mg/L., Triclabendazole demonstrated a fasciolicidal efficacy of 100% at a concentration of 10 and 50 mg/L at 24, 48 h and 72 hours post-treatment
Substance Class Chemical
Created
by admin
on Fri Jun 25 22:13:15 UTC 2021
Edited
by admin
on Fri Jun 25 22:13:15 UTC 2021
Record UNII
4784C8E03O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRICLABENDAZOLE
INN   MART.   MI  
USAN   INN  
Official Name English
1H-BENZIMIDAZOLE, 6-CHLORO-5-(2,3-DICHLOROPHENOXY)-2-(METHYLTHIO)-
Systematic Name English
NVP-EGA230
Code English
TRICLABENDAZOLE [MART.]
Common Name English
TRICLABENDAZOLE [ORANGE BOOK]
Common Name English
EGATEN
Brand Name English
TRICLABENDAZOLE [INN]
Common Name English
EGA230B
Code English
TRICLABENDAZOLE [MI]
Common Name English
5-CHLORO-6-(2,3-DICHLOROPHENOXY)-2-(METHYLTHIO)-1H-BENZIMIDAZOLE
Systematic Name English
TRICLABENDAZOLE [WHO-DD]
Common Name English
FASINEX
Brand Name English
TRICLABENDAZOLE [USAN]
Common Name English
NSC-759250
Code English
Classification Tree Code System Code
WHO-VATC QP52AC01
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
WHO-ATC P02BX04
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
FDA ORPHAN DRUG 564216
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.1.3
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
NCI_THESAURUS C250
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
FDA ORPHAN DRUG 525416
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
Code System Code Type Description
CAS
68786-66-3
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
EVMPD
SUB11267MIG
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
NCI_THESAURUS
C75236
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
MERCK INDEX
M11087
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY Merck Index
MESH
C039276
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
DRUG CENTRAL
2734
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
EPA CompTox
68786-66-3
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
RXCUI
2118525
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
LACTMED
Triclabendazole
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
FDA UNII
4784C8E03O
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
DRUG BANK
DB12245
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
ChEMBL
CHEMBL1086440
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
PUBCHEM
50248
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
INN
5003
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
WIKIPEDIA
TRICLABENDAZOLE
Created by admin on Fri Jun 25 22:13:16 UTC 2021 , Edited by admin on Fri Jun 25 22:13:16 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
MAJOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
TARGET ORGANISM->INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
TARGET ORGANISM->INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE ACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
FOR VETERINARY USE
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
FOR VETERINARY USE
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
FOR VETERINARY USE
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC